Codon Capital

Investing in world class Series A biotech companies inventing breakthrough therapeutics for human disease or synthetic biology solutions improving Earth. Codon Capital is a San Francisco-based biotech venture capital company, specializing in therapeutics and synthetic biology. Our series A investment approach is to fund startup teams that can execute on difficult technical, definable achievements that enable breakthrough biotech products. We’re investing in solutions to the most critical problems of human health and sustainability, and in teams who can make the impossible possible. This has allowed companies to exit via acquisition in less than 18 months from series A for multiples of 35X and 14X. Our early stage investments back teams to build enduring quality solutions, which sometimes are snapped up via acquisitions, but also have the option to raise additional equity at attractive valuations to seek even more value.